Basics Y-mAbs Therapeutics, Inc. IPO Date: September 17, 2018 Sector: Healthcare Industry: Biotech Market Cap: $199.7M Activated in VL: True Average Daily Range Avg Daily Range: $0.61 | 3.28% Avg Daily Range (30 D): $0.19 | 4.38% Avg Daily Range (90 D): $0.18 | 3.73% Institutional Daily Volume Avg Daily Volume: .25M Avg Daily Volume (30 D): .17M Avg Daily Volume (90 D): .28M Trade Size Avg Trade Size (Sh.): 78 Avg Trade Size (Sh.) (30 D): 66 Avg Trade Size (Sh.) (90 D): 69 Institutional Trades Total Inst.Trades: 1,102 Avg Inst. Trade: $1.39M Avg Inst. Trade (30 D): $.89M Avg Inst. Trade (90 D): $1.49M Avg Inst. Trade Volume: .06M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $1.44M Avg Closing Trade (30 D): $3.63M Avg Closing Trade (90 D): $2.07M Avg Closing Volume: 65.23K         News May 26, 2025 @ 2:00 PM Y-mAbs Presents GD2-SADA PRIT Trial in Progress Po... Source: Y-Mabs Therapeutics, Inc. Jul 1, 2024 @ 8:05 PM Y-mAbs Appoints Seasoned Biopharma Executive Peter... Source: Y-mAbs Therapeutics, Inc. Jun 7, 2024 @ 11:05 AM Y-mAbs Announces Preclinical GD2-SADA Data to be P... Source: Y-mAbs Therapeutics, Inc. Jun 5, 2024 @ 11:05 AM Y-mAbs Deepens Radiopharmaceutical Leadership with... Source: Y-mAbs Therapeutics, Inc. Jun 1, 2024 @ 12:15 PM Y-mAbs Announces Publication of Preclinical GD2-SA... Source: Y-mAbs Therapeutics, Inc. Financials   TTM Q1 2025 Q4 2024 Basic EPS $-.64 $-.12 $-.15 Diluted EPS $-.64 $-.12 $-.15 Revenue $ 88.66M $ 20.9M $ 26.5M Gross Profit $ 72.75M $ 17.9M $ 18.85M Net Income / Loss $ -28.23M $ -5.2M $ -6.79M Operating Income / Loss $ -30.84M $ -6.54M $ -5.94M Cost of Revenue $ 15.91M $ 3M $ 7.64M Net Cash Flow $ -6.92M $ -6.92M $ M PE Ratio